232 related articles for article (PubMed ID: 19385504)
21. Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factors.
Davis SN; Perkins JM
Endocr Pract; 2007; 13(7):790-804. PubMed ID: 18194939
[TBL] [Abstract][Full Text] [Related]
22. [Endocannabinoids--the new option in the treatment of metabolic syndrome and in smoking cessation].
Kvasnicka T
Cas Lek Cesk; 2005; 144(2):81-4; discussion 85. PubMed ID: 15807291
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoid-1 receptor antagonists in type-2 diabetes.
Scheen AJ
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):535-53. PubMed ID: 18054734
[TBL] [Abstract][Full Text] [Related]
24. [The endocannabinoid system].
Sudano I; Périat D; Noll G
Praxis (Bern 1994); 2008 Apr; 97(7):375-80. PubMed ID: 18548817
[TBL] [Abstract][Full Text] [Related]
25. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
[TBL] [Abstract][Full Text] [Related]
26. Endocannabinoid control of food intake and energy balance.
Di Marzo V; Matias I
Nat Neurosci; 2005 May; 8(5):585-9. PubMed ID: 15856067
[TBL] [Abstract][Full Text] [Related]
27. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
Silvestri C; Di Marzo V
Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
[TBL] [Abstract][Full Text] [Related]
28. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.
Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV
Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932
[TBL] [Abstract][Full Text] [Related]
29. Contribution of CB1 blockade to the management of high-risk abdominal obesity.
Després JP; Lemieux I; Alméras N
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S44-52. PubMed ID: 16570106
[TBL] [Abstract][Full Text] [Related]
30. Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk.
Rosenson RS
Cardiology; 2009; 114(3):212-25. PubMed ID: 19641317
[TBL] [Abstract][Full Text] [Related]
31. Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
Dibble CT; Gelfand EV; Cannon CP
Curr Atheroscler Rep; 2007 Nov; 9(5):359-66. PubMed ID: 18001618
[TBL] [Abstract][Full Text] [Related]
32. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system?
Kunos G
Am J Med; 2007 Sep; 120(9 Suppl 1):S18-24; discussion S24. PubMed ID: 17720356
[TBL] [Abstract][Full Text] [Related]
33. Investigations of the endocannabinoid system in adipose tissue: effects of obesity/ weight loss and treatment options.
Bennetzen MF
Dan Med Bull; 2011 Apr; 58(4):B4269. PubMed ID: 21466769
[TBL] [Abstract][Full Text] [Related]
34. Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors.
Woods SC
Am J Med; 2007 Mar; 120(3 Suppl 1):S19-25. PubMed ID: 17320518
[TBL] [Abstract][Full Text] [Related]
35. Endocannabinoid system and cardiometabolic risk.
Saavedra LE
Clin Pharmacol Ther; 2007 Nov; 82(5):591-4. PubMed ID: 17898706
[TBL] [Abstract][Full Text] [Related]
36. The challenge of treating obesity: the endocannabinoid system as a potential target.
Isoldi KK; Aronne LJ
J Am Diet Assoc; 2008 May; 108(5):823-31. PubMed ID: 18442506
[TBL] [Abstract][Full Text] [Related]
37. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
Scheen AJ; Paquot N
Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):103-16. PubMed ID: 19285264
[TBL] [Abstract][Full Text] [Related]
38. [Endocannabinoid system and energy metabolism: physiology and pathophysiology].
Pagotto U; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):74S-82S. PubMed ID: 18773754
[TBL] [Abstract][Full Text] [Related]
39. Endocannabinoids and their role in fatty liver disease.
Mallat A; Lotersztajn S
Dig Dis; 2010; 28(1):261-6. PubMed ID: 20460921
[TBL] [Abstract][Full Text] [Related]
40. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
Boekholdt SM; Jukema JW; Peters RJ
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
